Short-Course Tocilizumab May Increase HBV Reactivation in RA
Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.
Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.
In patients with rheumatoid arthritis, low baseline hepatitis B surface antibody titers are significant risk factors for HBV reactivation.
Antibody concentrations against antigen epitopes of the oral pathogen P gingivalis appear to increase prior to the onset of RA symptoms, suggesting that P gingivalis may be associated with RA pathogenesis.
A latent cytomegalovirus infection causes chronic infection phenotype in CD8+ cells.